Community hub
0 subscribers8 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to SAGE-324.
Nothing was collected or created yet.
SAGE-324
View on Wikipediafrom Wikipedia
 | |
| Clinical data | |
|---|---|
| Other names | BIIB124 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C24H38N4O3 |
| Molar mass | 430.593 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SAGE-324, also known as BIIB124, is an experimental drug. It is a neurosteroid that works as a GABAA receptor positive allosteric modulator.[1][2][3]
SAGE-324 was being developed by Biogen for the treatment of essential tremor.[4] Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials.[5]
References
[edit]- ^ Cerne, Rok; Lippa, Arnold; Poe, Michael M.; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Golani, Lalit K.; Cook, James M.; Witkin, Jeffrey M. (June 2022). "GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacology & Therapeutics. 234 108035. doi:10.1016/j.pharmthera.2021.108035. PMC 9787737.
- ^ Witkin, Jeffrey M.; Lippa, Arnold; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Biggerstaff, Andrew; Kivell, Bronwyn M.; Knutson, Daniel E.; Sharmin, Dishary; Pandey, Kamal P.; Mian, Md Yeunus; Cook, James M.; Cerne, Rok (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology Biochemistry and Behavior. 213 173321. doi:10.1016/j.pbb.2021.173321. PMID 35041859. S2CID 245963990.
- ^ Quagliato, Laiana A.; Carta, Mauro G.; Nardi, Antonio E. (September 2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID 36099401. S2CID 252219658.
- ^ Ondo, William (1 January 2022). "Chapter Eleven - Enhancing GABA inhibition is the next generation of medications for essential tremor". International Review of Neurobiology. Vol. 163. Academic Press. pp. 317–334. doi:10.1016/bs.irn.2022.02.007. ISBN 978-0-323-89974-1. PMID 35750368. S2CID 250022192.
- ^ "Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor". Biogen (Press release). 2024-07-24. Retrieved 2024-07-24.